Multicenter Phase II Study of Epitope Peptides with UFT/LV following curative resection for stage III Colorectal cancer

Multicenter Phase II Study of Epitope Peptides with UFT/LV following curative resection for stage III Colorectal cancer - Multicenter Phase II Study of Epitope Peptides with UFT/LV following curative resection for stage III Colorectal cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003552

Enrollment

110

Registered

2010-04-28

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III colorectal cancer

Interventions

HLA-A2402 positive HLA-A2402 negative

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histological proven stage III colorectal cancer 2. PS:0 to 1(ECOG performance status score) 3. 20-80 years old 4. Good function of critical organs 5. Written informed consents

Exclusion criteria

Exclusion criteria: 1.Plegnant 2. Breastfeeding 3. Wish for pregnancy 4. Active infection 5. Steroid or immunosuppressive therapy 6. Multiple cancer 7. Doctors opinion

Design outcomes

Primary

Measure	Time frame
recurrence rate	—

Secondary

Measure	Time frame
safety immune response	—

Countries

Japan

Contacts

Public ContactFumiaki Sugiura

Kinki University School of Medicine Department of Surgery

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026